Starbucks CEO Brian Niccol's role is discussed alongside market competition and investment potential in CancerVax.
1 report, 0 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Starbucks CEO Brian Niccol's role is discussed alongside market competition and investment potential in CancerVax.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Starbucks
American multinational coffee company
-
Brian Niccol
Chairman and CEO, Starbucks
-
CancerVax
American pharmaceutical company
Nothing else this week.
Related events
- Analyst notes detail how Dutch Bros is gaining market share from Starbucks amid broader fast-food competition.
- Brian Niccol is leading the 'Back to Starbucks' turnaround strategy, which is facing headwinds in international markets like China. TD Cowen upgraded the stock to Buy in mid-May.
- Starbucks CEO Brian Niccol guides company performance and outlook. Pfizer CEO Albert Bourla guides company performance and outlook. Both companies are evaluated as alternative investment targets.
- Starbucks reports an 8.1% comps increase in North America, anticipating continued U.S. growth of at least 6.5%.
Coverage
Newest first; wire copies grouped- Unknown outlet